Prognostic role of contraindictated drugs in hospitalised patients with decompensated heart failure
No Thumbnail Available
Authors
Parish, Olivia
Cannata, Antonio
Shamsi, Aamir
Jordan-Rios, Antonio
Albarjas, Mohammad
Piper, Susan
Scott, Paul
Bromage, Daniel
McDonagh, Theresa
Check for full-text access
Issue Date
2023
Type
Article
Language
Keywords
Alternative Title
Abstract
Due to the ageing population, patients often present to the hospital with a high burden of comorbidities and polypharmacy. For patients admitted with decompensated heart failure (HF), the evidence on the effects of contraindicated drugs on long-term mortality is scarce. Therefore, we aimed to investigate the effect of contraindicated medications on outcomes of patients admitted with decompensated HF. We analyzed all consecutive patients from the National Heart Failure Audit admitted to two tertiary centers with acutely decompensated HF between April 2020 and October 2021. We included medication classes listed as contraindicated (class III) in the most recent European and American guidelines on the management of HF. The primary outcome measure was in-hospital mortality. The secondary outcome measure was overall mortality. Overall, 716 patients admitted with acute HF were included. One-fifth (
Description
Citation
Publisher
License
Journal
The Journal of Pharmacology and Experimental Therapeutics
Volume
386
Issue
2